Aggarwal, R. R., Schweizer, M. T., Chay, C. H., Marathe, O., Araujo-Mino, E., Morris, D., Nanus, D. M., Narang, M., Spira, A. I., Schnadig, I. D., Attwell, S., Johnson, E., Wegge, P., Xu, V., Zhu, H., McGuire, A., Snyder, M., Sweeney, M., Lakhotia, S., Alumkal, J. J. (2025). A randomized, open-label, phase 2b study of the BET bromodomain inhibitor (BETi) ZEN-3694 plus enzalutamide vs. enzalutamide in patients with metastatic castration resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps5123